Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

April 27, 2021 by Alan Khadavi

Baricitinib for Atopic Dermatitis (Eczema)

Baricitinib is currently being studied for the treatment of atopic dermatitis. Baricitinib is part of the family of oral Janus kinase inhibitors that are an emerging modality in the treatment of chronic allergic inflammatory disorders due to their ability to inhibit signaling of multiple pathways of cytokines.

We discussed in another blog post, Abrocitinib which is also being studied for eczema. That drug is being developed by Pfizer. At this current time it is not available, but should be getting FDA approval soon.

Baricitinib, sold under the brand name Olumiant among others, is a drug for the treatment of rheumatoid arthritis in adults whose disease was not well controlled using RA medications called tumor necrosis factor antagonists.

In November 2020, the FDA issued an Emergency Use Authorization (EUA) for the combination of baricitinib with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized people two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Olumiant is current being manufactured by Lilly Pharmaceuticals, and its indication is a once-daily pill to treat adults with moderately to severely active rheumatoid arthritis (RA) who have tried at least one other medicine called a tumor necrosis factor (TNF) antagonist, such as Humira® (adalimumab), Enbrel® (etanercept), and Remicade® (infliximab), that did not work well or could not be tolerated.

In a recent study published in the JAMA Dermatology, a phase 3 placebo-controlled trial assessed the efficacy of baricitinib in patients with moderate-to-severe atopic dermatitis in combination with a topical steroid. At week 16, 31% of patients treated with 4 mg and 24% of patients treated with 2 mg of baricitinib once daily achieved clear or almost clear skin assessed by the Investigator Global Assessment for Atopic Dermatitis score (IGA) , compared with 15% of patients treated with topical steroids alone.

Baricitinib was well tolerated. There seems to be a clinical benefit for the combo treatment of baricitinib with topical steroids.

The first author of the study Dr. Kristian Reich stated “The combination of novel systemic therapies such as baricitinib with topical treatment modalities evolves as the standard in the treatment of patients with more severe atopic dermatitis. The study shows that about one third of patients receiving this combination therapy are likely to achieve a high level of skin improvement.”

It will be interesting when aborcitinib and baricitinib are both approved, which drug will do clinically better. But most of all how will these Janus Kinase inhibitors compare to Dupixent (dupiliumb) which has become the “go to” treatment for patients with severe eczema. Dupixent is a self injection every 2 weeks, whereas the Janus Kinase inhibitors are once daily pills. There are some associated side effects with Dupixent, notably conjunctivitis. The Janus Kinase inhibitors are already on the market for other conditions, notably rheumatoid arthritis.

Dupilumab (Dupixent) for Atopic Dermatitis (Eczema) Sufferers

Dupixent (Dupilumab) for Atopic Dermatitis/Eczema

 

Filed Under: atopic dermatitis, Blog, Medications

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page